|
시장보고서
상품코드
1997069
유전자 치료 CDMO 시장 규모와 예측(2021-2034년) : 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 - 서비스 유형별, 최종사용자, 지역별Gene Therapy CDMO Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type, End User, and Geography |
||||||
유전자 치료 CDMO 시장 규모는 2025년 26억 달러에서 2034년까지 141억 7,000만 달러로 확대될 것으로 예상되며, 2026-2034년 연평균 복합 성장률(CAGR) 20.3%를 나타낼 것으로 예측됩니다. 만성질환 및 유전질환의 유병률 증가, 규제 당국의 승인 및 상업화 급증, 기업의 유전자치료제 제조 아웃소싱 확산은 유전자치료제 CDMO 시장 규모 확대에 기여하는 주목할 만한 요인으로 꼽히고 있습니다. 또한, 맞춤형 치료와 희귀질환 치료에 대한 수요 증가는 가까운 미래에 유전자치료 CDMO 시장에 새로운 트렌드를 가져올 것으로 예측됩니다.
자동화와 디지털화가 효율성과 확장성 향상 및 품질관리 개선을 가져오는 것으로, 시장은 변혁을 이루고 있습니다.이러한 기술은 바이러스 벡터 생산이나 세포 증식을 취급하는 절차를 합리화하는 것과 동시에, 인적 관여 필요성을 최소한으로 억제하기 위해, 맞춤형 치료법 개발로부터 생기는 복잡한 과제를 해결합니다.CDMO는 프로세스 분석 기술을 도입해 조업을 실시간으로 감시하고 있어, 이것에 의해 복수 제품 동시 생산을 유지하면서, 처리 방법을 조정하는 것이 가능하게 됩니다.디지털 트윈은 그 예측 기능을 활용하고, 다른 시험 조건하에서 세포가 어떻게 반응하는지를 예측해, 공장 프로세스 개선에 기여 합니다.자르트리아스사 MODDE 소프트웨어와 Ambr 15바이오리액터 편성은 디지털 트윈 기술이 가상 트윈 시스템을 통해서 최적화를 실현하는 방법을 나타내고 있습니다.바이러스 벡터 최적화 프로세스에서는 pH 및 세포 밀도 파라미터 정밀한 조정에 의해 실험 기간을 8주간부터 3주간에 대폭 단축하는 것과 동시에, 감염 역가를 10배에 높이는 것에 성공했습니다.
머신러닝 알고리즘과 예측 기능을 결합하여 CDMO는 치료 제품의 품질과 양을 향상시키면서 가동 중단을 줄이기 위한 예방적 조치를 취할 수 있습니다. 2024년 10월, 옴니아바이오는 캐나다 온타리오주 해밀턴에 상업적 생산이 가능한 새로운 제조 시설과 AI 우수성 센터를 오픈했습니다. 10만 평방피트 규모의 이 시설은 세포 및 유전자 치료제 생산에 특화된 최대 규모의 CDMO 중 하나로 꼽힙니다.
유전자치료제 제조에 대한 규제 요건에 따라 조직은 제조 공정 전반에 걸쳐 방대한 데이터를 수집하고 분석해야 합니다. AI와 디지털 툴은 원활한 데이터 통합을 가능하게 하고, 규제 당국의 심사에 필요한 모든 문서가 완전하고 정확하도록 보장합니다. AI와 디지털 플랫폼을 함께 사용하는 CDMO는 변화하는 업계 요구 사항을 준수하면서 규제 당국에 대한 신청 프로세스의 복잡한 특성을 효과적으로 처리할 수 있습니다.
자동화와 인공지능, 디지털 분석 시스템을 결합한 접근 방식은 CDMO가 운영 효율성을 달성하기 위한 주요 방법으로 유전자 치료 CDMO 시장에서 중요한 트렌드로 부상하고 있습니다.
최종 사용자별 인사이트
최종 사용자별로 유전자 치료 CDMO 시장은 제약사, 바이오 제약사, 기타 최종 사용자로 구분됩니다. 2025년에는 바이오 제약 회사 부문이 유전자 치료 CDMO 시장에서 가장 큰 점유율을 차지할 것으로 예측됩니다. 유전자 치료 CDMO 시장은 주로 제품 개발 및 제조 활동에서 외부의 도움을 필요로 하는 소규모 생명공학 기업 및 스타트업 기업을 포함한 바이오 제약 회사가 주도하고 있습니다. 기업의 확장은 사내 생산능력의 부족, 고가의 연구개발비, 그리고 일반적으로 기업이 보유하지 않은 특수 의료시설과 전문적 기술지식을 필요로 하는 유전자 치료의 어려움에 기인합니다. 기업들은 아웃소싱을 활용하여 임상 파이프라인의 개발 프로세스를 개선하고 R&D 활동의 예산을 유지하면서 임상 파이프라인의 개발 프로세스를 개선하고 있습니다. 수천 개의 개발 자산을 보유한 유전자치료제 파이프라인이 확대됨에 따라 생명공학 기업들이 바이러스 벡터 생산, 공정 최적화 및 GMP 제조 서비스에서 신뢰할 수 있는 파트너가 필요함에 따라 수요가 증가하고 있습니다. 주요 사례로는 종양학 및 희귀질환 분야의 수많은 바이오테크 프로그램을 지원하고 있는 론자(Lonza), 카탈렌트(Catalent)와 같은 대형 CDMO와의 파트너십을 들 수 있습니다. 길리어드 사이언스(Kite Pharma를 통해)와 암젠도 유전자 변형 치료제의 첨단 개발에 CDMO 서비스를 활용하고 있습니다. 바이오텍 기업들은 규제 문제를 극복하기 위해 CDMO 서비스를 이용하고 있으며, 이를 통해 제품을 보다 빠르게 시장에 출시할 수 있게 되어 유전자 치료 CDMO 시장의 성장을 가속하고 있습니다.
목차
제1장 주요 요약
제2장 유전자 치료 CDMO 시장 구도
제3장 경쟁 구도
제4장 유전자 치료 CDMO 시장 - 주요 시장 역학
제5장 유전자 치료 CDMO 시장 - 세계 시장 분석
제6장 유전자 치료 CDMO 시장 매출 분석 - 서비스 유형별
제7장 유전자 치료 CDMO 시장 매출 분석 - 최종사용자
제8장 유전자 치료 CDMO 시장 - 지역 분석
제9장 유전자 치료 CDMO 시장 상황
제10장 유전자 치료 CDMO 시장 - 주요 기업 개요
제11장 부록
LSH 26.04.20The gene therapy CDMO market size is expected to grow from US$ 2.60 billion in 2025 to US$ 14.17 billion by 2034; it is projected to register a CAGR of 20.3% during 2026-2034. The increasing prevalence of chronic and genetic diseases, surging regulatory approvals and commercialization, and growing popularity of outsourcing gene therapy manufacturing by companies are noteworthy factors contributing to the expansion of the gene therapy CDMO market size. Additionally, the growing demand for personalized and rare disease therapies are projected to bring new gene therapy CDMO market trends in the near future.
The market experiences a transformation because automation and digitalization bring better efficiency and scalability and improved quality control. The technologies solve complex challenges which arise from developing personalized therapies because they minimize the need for human participation while they streamline the procedures which handle viral vector production and cell expansion. CDMOs implement process analytical technologies to monitor their operations in real time which allows them to adjust their processing methods while maintaining simultaneous production of multiple items. Digital twins use their predictive capabilities to forecast how cells will react under different testing conditions, which helps to improve factory processes. The combination of Sartorius's MODDE software with Ambr 15 bioreactors demonstrates how digital twin technology enables optimization through virtual twin systems. The process of viral vector optimization achieved a significant reduction in experimental duration to three weeks from eight weeks while it generated a tenfold rise in infectious titer through precise adjustment of pH and cell density parameters.
The use of machine learning algorithms together with predictive capabilities enables CDMOs to implement proactive measures which decrease operational interruptions while enhancing the therapeutic product quality and quantity. In October 2024, OmniaBio opened its new commercial-ready manufacturing facility and AI center of excellence in Hamilton, Ontario, Canada. The facility which covers 100,000 square feet stands among the biggest CDMOs which focus on manufacturing cell and gene therapies.
The regulatory requirements for gene therapy manufacturing necessitate organizations to collect and analyze extensive data throughout their manufacturing processes. AI and digital tools enable seamless data integration, ensuring that all necessary documentation is complete and accurate for regulatory review. CDMOs that use AI together with digital platforms can effectively handle the complex nature of regulatory submission processes while they maintain compliance with changing industry requirements.
Automation together with artificial intelligence and digital analytics systems has become the key approach for CDMOs to achieve operational efficiency through their implementation, thereby emerging as a significant trend in the gene therapy CDMO market.
End User-Based Insights
Based on end user, the gene therapy CDMO market is segmented into pharmaceutical companies, biopharmaceutical companies, and other end users. The biopharmaceutical companies segment held the largest gene therapy CDMO market share in 2025. The gene therapy CDMO market is mainly controlled by biopharmaceutical companies which include small biotech firms and startup companies that need outside help for their product development and manufacturing activities. The company's expansion results from its incomplete internal capacity combined with expensive research and development expenses and the difficult nature of gene therapy treatments which need special medical facilities and expert technical knowledge that the company usually does not possess. The company uses outsourcing to improve its clinical pipeline development process while maintaining its budget for research and development activities. The expanding gene therapy pipeline, with thousands of assets in development, creates increasing demand as biotechs require trustworthy partners for their needs in viral vector production and process optimization and GMP manufacturing services. Key examples include collaborations with leading CDMOs like Lonza and Catalent which support numerous biotech programs in oncology and rare diseases. Gilead Sciences (via Kite Pharma) and Amgen have also used CDMO services for their advanced development of gene-modified therapies. The biotechs use CDMO services to overcome their regulatory challenges which enables them to bring products to market faster, thereby fueling the gene therapy CDMO market growth.
The World Health Organization and Australian Institute of Health and Welfare are among the primary and secondary sources referred to while preparing the gene therapy CDMO market report.
Table Of Contents
1. Executive Summary
- 1.1 Analyst Market Outlook
- 1.2 Market Attractiveness
2. Gene Therapy CDMO Market Landscape
- 2.1 Overview
- 2.2 Value Chain Analysis
- 2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
- 2.4 Porter's Five Force Analysis
- 2.5 PEST Analysis
- 2.6 Import-Export Analysis for Key Countries (As per the nearest HS Code)
- 2.6.1 Import-Export Analysis for Key Countries
- 2.7 Impact of Artificial Intelligence (AI)
- 2.8 Product or Technology Roadmap
- 2.9 Sustainability and ESG Trends
- 2.10 Patent Analysis
- 2.11 Regulatory Framework
3. Competitive Landscape
- 3.1 Company Benchmarking by Key Players
- 3.2 Market Share Analysis, 2025 - By Key Players
- 3.3 Market Concentration
4. Gene Therapy CDMO Market - Key Industry Dynamics
- 4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic and Genetic Diseases
- 4.1.2 Surging Regulatory Approvals and Commercialization
- 4.1.3 Growing Popularity of Outsourcing Gene Therapy Manufacturing by Companies
- 4.2 Market Restraints
- 4.2.1 High Manufacturing Costs
- 4.2.2 Complexities in Manufacturing Processes
- 4.2.3 Complex Regulatory and Compliance Requirements
- 4.3 Market Opportunities
- 4.3.1 Increased Clinical Trials for Innovative Therapies
- 4.3.2 Strategic Initiatives by Companies
- 4.3.3 Expansion of Commercial Manufacturing Services
- 4.4 Future Trends
- 4.4.1 Advanced Automation and Digitalization
- 4.4.2 Personalized and Rare Disease Therapies Demand
- 4.4.3 Scalable Viral Vector and Next Gen Production Technologies
- 4.5 Impact of Drivers and Restraints
5. Gene Therapy CDMO Market - Global Market Analysis
- 5.1 Gene Therapy CDMO Market Revenue (US$ Million), 2021-2034
- 5.2 Gene Therapy CDMO Market Forecast and Analysis
6. Gene Therapy CDMO Market Revenue Analysis -Service Type
- 6.1 Gene Therapy CDMO Market Forecasts and Analysis by Service Type
- 6.1.1 Drug Development and Manufacturing
- 6.1.1.1 Overview
- 6.1.1.2 Drug Development and Manufacturing: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
- 6.1.2 Testing and Regulatory Services
- 6.1.2.1 Overview
- 6.1.2.2 Testing and Regulatory Services: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
- 6.1.3 Other Service Types
- 6.1.3.1 Overview
- 6.1.3.2 Other Service Types: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
- 6.1.1 Drug Development and Manufacturing
7. Gene Therapy CDMO Market Revenue Analysis -End User
- 7.1 Gene Therapy CDMO Market Forecasts and Analysis by End User
- 7.1.1 Pharmaceutical Companies
- 7.1.1.1 Overview
- 7.1.1.2 Pharmaceutical Companies: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
- 7.1.2 Biopharmaceutical Companies
- 7.1.2.1 Overview
- 7.1.2.2 Biopharmaceutical Companies: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
- 7.1.3 Other End Users
- 7.1.3.1 Overview
- 7.1.3.2 Other End Users: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
- 7.1.1 Pharmaceutical Companies
8. Gene Therapy CDMO Market - Geographical Analysis
- 8.1 North America
- 8.1.1 North America Gene Therapy CDMO Market Overview
- 8.1.2 North America: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.1.3 North America: Gene Therapy CDMO Market- By Segmentation
- 8.1.3.1 Service Type
- 8.1.3.2 End User
- 8.1.4 North America: Gene Therapy CDMO Market Breakdown by Countries
- 8.1.4.1 United States Market
- 8.1.4.1.1 United States: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.1.4.1.2 United States: Gene Therapy CDMO Market- By Segmentation
- 8.1.4.1.2.1 Service Type
- 8.1.4.1.2.2 End User
- 8.1.4.2 Canada Market
- 8.1.4.2.1 Canada: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.1.4.2.2 Canada: Gene Therapy CDMO Market- By Segmentation
- 8.1.4.2.2.1 Service Type
- 8.1.4.2.2.2 End User
- 8.1.4.3 Mexico Market
- 8.1.4.3.1 Mexico: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.1.4.3.2 Mexico: Gene Therapy CDMO Market- By Segmentation
- 8.1.4.3.2.1 Service Type
- 8.1.4.3.2.2 End User
- 8.1.4.1 United States Market
- 8.2 Europe
- 8.2.1 Europe Gene Therapy CDMO Market Overview
- 8.2.2 Europe: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.2.3 Europe: Gene Therapy CDMO Market- By Segmentation
- 8.2.3.1 Service Type
- 8.2.3.2 End User
- 8.2.4 Europe: Gene Therapy CDMO Market Breakdown by Countries
- 8.2.4.1 Germany Market
- 8.2.4.1.1 Germany: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.2.4.1.2 Germany: Gene Therapy CDMO Market- By Segmentation
- 8.2.4.1.2.1 Service Type
- 8.2.4.1.2.2 End User
- 8.2.4.2 United Kingdom Market
- 8.2.4.2.1 United Kingdom: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.2.4.2.2 United Kingdom: Gene Therapy CDMO Market- By Segmentation
- 8.2.4.2.2.1 Service Type
- 8.2.4.2.2.2 End User
- 8.2.4.3 France Market
- 8.2.4.3.1 France: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.2.4.3.2 France: Gene Therapy CDMO Market- By Segmentation
- 8.2.4.3.2.1 Service Type
- 8.2.4.3.2.2 End User
- 8.2.4.4 Italy Market
- 8.2.4.4.1 Italy: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.2.4.4.2 Italy: Gene Therapy CDMO Market- By Segmentation
- 8.2.4.4.2.1 Service Type
- 8.2.4.4.2.2 End User
- 8.2.4.5 Spain Market
- 8.2.4.5.1 Spain: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.2.4.5.2 Spain: Gene Therapy CDMO Market- By Segmentation
- 8.2.4.5.2.1 Service Type
- 8.2.4.5.2.2 End User
- 8.2.4.6 Rest of Europe Market
- 8.2.4.6.1 Rest of Europe: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.2.4.6.2 Rest of Europe: Gene Therapy CDMO Market- By Segmentation
- 8.2.4.6.2.1 Service Type
- 8.2.4.6.2.2 End User
- 8.2.4.1 Germany Market
- 8.3 Asia Pacific
- 8.3.1 Asia Pacific Gene Therapy CDMO Market Overview
- 8.3.2 Asia Pacific: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.3.3 Asia Pacific: Gene Therapy CDMO Market- By Segmentation
- 8.3.3.1 Service Type
- 8.3.3.2 End User
- 8.3.4 Asia Pacific: Gene Therapy CDMO Market Breakdown by Countries
- 8.3.4.1 China Market
- 8.3.4.1.1 China: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.3.4.1.2 China: Gene Therapy CDMO Market- By Segmentation
- 8.3.4.1.2.1 Service Type
- 8.3.4.1.2.2 End User
- 8.3.4.2 Japan Market
- 8.3.4.2.1 Japan: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.3.4.2.2 Japan: Gene Therapy CDMO Market- By Segmentation
- 8.3.4.2.2.1 Service Type
- 8.3.4.2.2.2 End User
- 8.3.4.3 India Market
- 8.3.4.3.1 India: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.3.4.3.2 India: Gene Therapy CDMO Market- By Segmentation
- 8.3.4.3.2.1 Service Type
- 8.3.4.3.2.2 End User
- 8.3.4.4 Australia Market
- 8.3.4.4.1 Australia: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.3.4.4.2 Australia: Gene Therapy CDMO Market- By Segmentation
- 8.3.4.4.2.1 Service Type
- 8.3.4.4.2.2 End User
- 8.3.4.5 South Korea Market
- 8.3.4.5.1 South Korea: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.3.4.5.2 South Korea: Gene Therapy CDMO Market- By Segmentation
- 8.3.4.5.2.1 Service Type
- 8.3.4.5.2.2 End User
- 8.3.4.6 Rest of APAC Market
- 8.3.4.6.1 Rest of APAC: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.3.4.6.2 Rest of APAC: Gene Therapy CDMO Market- By Segmentation
- 8.3.4.6.2.1 Service Type
- 8.3.4.6.2.2 End User
- 8.3.4.1 China Market
- 8.4 Middle East and Africa
- 8.4.1 Middle East and Africa Gene Therapy CDMO Market Overview
- 8.4.2 Middle East and Africa: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.4.3 Middle East and Africa: Gene Therapy CDMO Market- By Segmentation
- 8.4.3.1 Service Type
- 8.4.3.2 End User
- 8.4.4 Middle East and Africa: Gene Therapy CDMO Market Breakdown by Countries
- 8.4.4.1 Saudi Arabia Market
- 8.4.4.1.1 Saudi Arabia: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.4.4.1.2 Saudi Arabia: Gene Therapy CDMO Market- By Segmentation
- 8.4.4.1.2.1 Service Type
- 8.4.4.1.2.2 End User
- 8.4.4.2 South Africa Market
- 8.4.4.2.1 South Africa: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.4.4.2.2 South Africa: Gene Therapy CDMO Market- By Segmentation
- 8.4.4.2.2.1 Service Type
- 8.4.4.2.2.2 End User
- 8.4.4.3 United Arab Emirates Market
- 8.4.4.3.1 United Arab Emirates: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.4.4.3.2 United Arab Emirates: Gene Therapy CDMO Market- By Segmentation
- 8.4.4.3.2.1 Service Type
- 8.4.4.3.2.2 End User
- 8.4.4.4 Rest of Middle East and Africa Market
- 8.4.4.4.1 Rest of Middle East and Africa: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.4.4.4.2 Rest of Middle East and Africa: Gene Therapy CDMO Market- By Segmentation
- 8.4.4.4.2.1 Service Type
- 8.4.4.4.2.2 End User
- 8.4.4.1 Saudi Arabia Market
- 8.5 South and Central America
- 8.5.1 South and Central America Gene Therapy CDMO Market Overview
- 8.5.2 South and Central America: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.5.3 South and Central America: Gene Therapy CDMO Market- By Segmentation
- 8.5.3.1 Service Type
- 8.5.3.2 End User
- 8.5.4 South and Central America: Gene Therapy CDMO Market Breakdown by Countries
- 8.5.4.1 Brazil Market
- 8.5.4.1.1 Brazil: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.5.4.1.2 Brazil: Gene Therapy CDMO Market- By Segmentation
- 8.5.4.1.2.1 Service Type
- 8.5.4.1.2.2 End User
- 8.5.4.2 Argentina Market
- 8.5.4.2.1 Argentina: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.5.4.2.2 Argentina: Gene Therapy CDMO Market- By Segmentation
- 8.5.4.2.2.1 Service Type
- 8.5.4.2.2.2 End User
- 8.5.4.3 Rest of South and Central America Market
- 8.5.4.3.1 Rest of South and Central America: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 8.5.4.3.2 Rest of South and Central America: Gene Therapy CDMO Market- By Segmentation
- 8.5.4.3.2.1 Service Type
- 8.5.4.3.2.2 End User
- 8.5.4.1 Brazil Market
9. Gene Therapy CDMO Market Industry Landscape
10. Gene Therapy CDMO Market - Key Company Profiles
- 10.1 WuXi Biologics Inc
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
- 10.2 Charles River Laboratories International Inc
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
- 10.3 Catalent Inc
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
- 10.4 Lonza Group AG
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
- 10.5 National Resilience Inc
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
- 10.6 Thermo Fisher Scientific Inc
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
- 10.7 AGC Biologics AS
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
- 10.8 Takara Bio Inc
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
- 10.9 FUJIFILM Holdings Corp
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments
- 10.10 SK pharmteco Inc
- 10.10.1 Key Facts
- 10.10.2 Business Description
- 10.10.3 Products and Services
- 10.10.4 Financial Overview
- 10.10.5 SWOT Analysis
- 10.10.6 Key Developments
11. Appendix
- 11.1 Glossary
- 11.4 Research Methodology and Approach
- 11.4.1 Secondary Research
- 11.4.2 Primary Research
- 11.4.3 Market Estimation Approach
- 11.4.3.1 Supply Side Analysis
- 11.4.3.2 Demand Side Analysis
- 11.4.4 Research Assumptions and Limitations
- 11.4.5 Currency Conversion
- 11.5 About The Insight Partners
- 11.6 Market Intelligence Cloud
